PMID- 28315555
OWN - NLM
STAT- MEDLINE
DCOM- 20171030
LR  - 20180208
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 21
IP  - 2 Suppl
DP  - 2017 Apr 1
TI  - Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their 
      Management
.
PG  - 45-52
LID - 10.1188/17.CJON.S2.45-52 [doi]
AB  - BACKGROUND: Immunotherapy, specifically the use of checkpoint inhibitors, offers 
      patients with cancer an alternative to chemotherapy, targeting different pathways 
      to destroy cancer cells. The side effects of immunotherapies, as well as their 
      impact on normal tissue, need to be assessed and managed based on their 
      mechanisms of action. OBJECTIVES: This article presents an overview of 
      immune-related adverse events (AEs). 
. METHODS: Common immune-related 
      toxicities, as well as rare and refractory toxicities, are reviewed. 
. FINDINGS: 
      Immunotherapy treatment is an option for many patients with cancer, and nurses 
      must understand the distinct side effect profile of these agents. Prompt 
      identification and expert management are the cornerstones of success when dealing 
      with immune-related AEs, and oncology nurses play a key role in improving patient 
      care.
FAU - Gordon, RuthAnn
AU  - Gordon R
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Kasler, Mary Kate
AU  - Kasler MK
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Stasi, Kristen
AU  - Stasi K
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Shames, Yelena
AU  - Shames Y
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Errante, Mimma
AU  - Errante M
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Ciccolini, Kathryn
AU  - Ciccolini K
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Skripnik Lucas, Anna
AU  - Skripnik Lucas A
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Raasch, Pam
AU  - Raasch P
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Fischer-Cartlidge, Erica
AU  - Fischer-Cartlidge E
AD  - Memorial Sloan Kettering Cancer Center.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antibodies, Monoclonal)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/*adverse effects/*therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/*etiology/*nursing
MH  - Education, Nursing, Continuing
MH  - Female
MH  - Humans
MH  - Immunotherapy/adverse effects/nursing
MH  - Male
MH  - Melanoma/drug therapy/*immunology/*nursing
MH  - Middle Aged
MH  - Oncology Nursing/*standards
MH  - Practice Guidelines as Topic
OTO - NOTNLM
OT  - cancer immunotherapy, immune-related adverse events, checkpoint inhibitors
EDAT- 2017/03/21 06:00
MHDA- 2017/10/31 06:00
CRDT- 2017/03/19 06:00
PHST- 2017/03/19 06:00 [entrez]
PHST- 2017/03/21 06:00 [pubmed]
PHST- 2017/10/31 06:00 [medline]
AID - 10.1188/17.CJON.S2.45-52 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2017 Apr 1;21(2 Suppl):45-52. doi: 10.1188/17.CJON.S2.45-52.